Industry Reports
Bristol-Myers Squibb to Announce Results for Second Quarter 2016 on July 28
Bristol-Myers Squibb Company will announce results for the second quarter of 2016 on Thursday, July 28, 2016. During a conference call at 10:30 a.m....
News
Ironwood and Allergan Announce New Drug Application for 72 mcg Linaclotide Has Been Accepted for FDA Review
Ironwood Pharmaceuticals, Inc.and Allergan plc announced that the U.S. FDA has accepted for review the supplemental New Drug Application (sNDA) for the 72 mcg...
Press Releases
PCI Pharma Services’ Hay-on-Wye Site Launches New 3D Camera Technology from Scanware
PCI Pharma Services is installing specialist, innovative three-dimensional (3D) and high resolution color camera technology for product inspection and fill control on three of...
Drug Research
Takeda Pharmaceutical Company Licenses Global Rights to Theravance Biopharma’s TD-8954
Takeda and Theravance Biopharma, Inc. announced that the companies have entered into a global license, development and commercialization agreement for TD-8954, a selective 5-HT4...
News
Merck Expands its Investment Fund Merck Ventures
• Existing biopharma venture fund renamed and expanded to all Merck business sectors• Newly established teams will focus on each of the three existing...
Press Releases
Pfizer Announces FDA Advisory Committees Recommend ALO-02 Extended-Release Capsules For Approval
Pfizer Inc. announced that the U.S. FDA Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee voted (9...
Press Releases
Janssen Phase 3 Data Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression and Improved Signs
Janssen Research & Development, LLC announced results from a pivotal Phase 3 study evaluating subcutaneous sirukumab (CNTO 136), a human anti-interleukin (IL)-6 monoclonal antibody...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read